We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.
- Authors
Aihara, Makoto; Ropo, Auli; Lu, Fenghe; Kawata, Hisashi; Iwata, Akihiro; Odani-Kawabata, Noriko; Shams, Naveed
- Abstract
Purpose: Omidenepag isopropyl (OMDI) is the prodrug of omidenepag, a selective, non-prostaglandin, prostanoid EP2 receptor agonist, which has been shown to lower intraocular pressure (IOP) in patients with glaucoma and ocular hypertension (OHT). This study evaluated the efficacy and safety of OMDI ophthalmic solution 0.002% in patients with primary open-angle glaucoma or OHT who were non-/low responders to latanoprost. Study design: Open-label, multicenter, Phase 3 study (NCT02822742). Methods: Following 1–4-week washout, patients were treated with latanoprost ophthalmic solution 0.005% during an 8-week run-in period. Patients with ≤15% IOP reduction at the end of the run-in (indicating non-/low response) received OMDI 0.002% (one drop once daily for 4 weeks). The primary endpoint was the change from baseline in mean diurnal IOP at Week 4. Results: In total, 26 patients were treated with OMDI; two withdrew owing to lack of efficacy. The mean diurnal IOP at baseline (end of latanoprost run-in) was 23.1 mmHg (7.6% IOP reduction from end of washout) indicating non-/low response to latanoprost. After 4 weeks of OMDI treatment, mean diurnal IOP was significantly reduced from baseline (−2.99 mmHg; P < 0.0001). No serious adverse events were reported. Adverse events occurred in five patients (19.2%); adverse drug reactions (anterior chamber cell, conjunctival hyperemia, and erythema of eyelid) occurred in two patients (7.7%) and were mild in severity. Conclusions: In this study, OMDI 0.002% demonstrated a clinically significant reduction in IOP and was well tolerated in patients with primary open-angle glaucoma and OHT who were non-/low responders to latanoprost.
- Subjects
FUJIFILM Corp.; OPEN-angle glaucoma; OCULAR hypertension; DRUG side effects; INTRAOCULAR pressure
- Publication
Japanese Journal of Ophthalmology, 2020, Vol 64, Issue 4, p398
- ISSN
0021-5155
- Publication type
Article
- DOI
10.1007/s10384-020-00748-x